Vir Biotechnology (VIR) Liabilities and Shareholders Equity (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 21.57% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.2 billion (down 27.82% YoY), and the FY2025 full-year result was $1.0 billion, down 28.31% from the prior year.
• Liabilities and Shareholders Equity advanced to $1.0 billion in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.9 billion in Q1 2022 to a low of $1.0 billion in Q4 2025.
• A 5-year average of $1.9 billion and a median of $1.8 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 154.24% in 2022 and sank 32.71% in 2024, its largest moves.
• Tracing VIR's Liabilities and Shareholders Equity over 5 years: stood at $2.8 billion in 2022, then slumped by 31.51% to $1.9 billion in 2023, then decreased by 27.11% to $1.4 billion in 2024, then slipped by 28.31% to $1.0 billion in 2025, then climbed by 2.27% to $1.0 billion in 2026.
• Business Quant data shows VIR's Liabilities and Shareholders Equity at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.